Develops cellular therapies for heart and brain diseases.
Jun 2026Revenue $1.19M/yrExpenses $24.8M/yr
No trendCash runway ≈ 6 months from Jun 2026
Figures by year
When will Longeveron be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $1.19M and expenses $24.8M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $1.20M | $24.5M | −$23.3M |
| Dec 2024 | $2.39M | $18.9M | −$16.5M |
| Dec 2023 | $709K | $21.7M | −$21.0M |
| Dec 2022 | $1.22M | $19.3M | −$18.0M |
| Dec 2021 | $1.31M | $18.8M | −$17.5M |
| Dec 2020 | $5.63M | $9.41M | −$3.78M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.